Blog

Beyond compliance: What ICH M15 means for the future of drug development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

Certara2026 年 6 月 9 日

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

Certara2026 年 6 月 2 日

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-Bodnar2026 年 5 月 28 日

Blog

Certainty US 2026 recap: Advancing model-informed drug development right from the start

This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…

Certara2026 年 5 月 26 日

Publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

Certara2026 年 5 月 21 日

On-Demand Webinar

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…

Certara2026 年 5 月 20 日

Blog

4 key principles of effective pharmacokinetic data reporting

Improve pharmacokinetic data reports with clear structure, effective visuals, and strong data presentation for actionable…

Certara2026 年 5 月 11 日

On-Demand Webinar

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.

Danielle Pillsbury2026 年 5 月 8 日

Blog

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 5 月 8 日 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

Certara2026 年 5 月 8 日

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

Certara2026 年 5 月 7 日

Modeling and Simulation – PK/PD

Beyond compliance: What ICH M15 means for the future of drug development

Applying AI-Driven Biosimulation to Drug Discovery

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

Certainty US 2026 recap: Advancing model-informed drug development right from the start

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

4 key principles of effective pharmacokinetic data reporting

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

Designing Drug Development Programs for Reimbursement Success

订阅时事通讯

快捷链接

解决方案

联系我们